Biopharmaceutical company AtaiBeckley has released positive topline data from the Phase IIb trial of BPL-003 in patients with treatment-resistant depression (TRD). 

In the open-label study, BPL-003 met response and remission criteria for depression, with clinically meaningful antidepressant effects sustained up to eight weeks. Patients receiving an 8mg dose recorded a 67% remission rate at Day 57, which was registered at 48% in patients receiving 12mg at the same timepoint. 

The trial showed that BPL-003 was generally well-tolerated, in line with other previously reported studies of the psychedelic class. The majority of adverse events occurred on the day of dosing and were classified as mild or moderate in severity and transient in nature. 

Depression is a debilitating and life-changing condition affecting nearly 300 million people across the globe. TRD occurs when a patient does not respond to two or more courses of antidepressants, with some studies showing that it may affect up to 50% of those living with depression.  

TRD is associated with higher rates of comorbid anxiety, sexual dysfunction, cognitive impairment, and reduced quality of life compared to non-resistant forms of depression. The condition places a significant burden on patients, caregivers, and healthcare systems, with elevated healthcare utilisation and substantial societal costs. 

AtaiBeckley now intends to advance into a Phase III clinical trial, with initiation expected to be in the second quarter of 2026. 

 

Bruno Quinney, Content Team, DDW